Oral Aleniglipron Reduced Weight at 36 Weeks - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

  • By

  • Kathryn Wighton

  • July 16, 2026

  • 6 min

Share

  • 1

    Aleniglipron reduced body weight by 9% to 12% at 36 weeks in adults with obesity or overweight, compared to 1% with placebo.

  • 2

    The ACCESS trial involved 230 patients, aged 18 to 79 years, with a mean BMI of 39.5 kg/m² and a mean weight of 114.8 kg.

  • 3

    Gastrointestinal adverse events were common, occurring in 79% to 89% of aleniglipron-treated patients, with nausea being the most frequent.

  • 4

    At week 56, mean weight loss was 13.3%, 16.2%, and 15.3% for patients initially assigned to 45 mg, 90 mg, and 120 mg, respectively.

  • 5

    The study had limitations, including a predominantly White population and lower female participation compared to other obesity trials.

Original Source(s)

Oral Aleniglipron Reduced Weight at 36 Weeks

  • by Kathryn Wighton

  • July 16, 2026

Related Content

Early-Phase Data Support Novel Contrast Agent

ASE 2026 data support further development of MVT-100 in pivotal trials.

FDA Monthly Preview: Key July Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

GLP-1 Drugs Tied to Smell, Taste Changes

A matched electronic health record study of more than 876,000 patients with type 2 diabetes found a low absolute incidence but higher relative hazard of documented smell and taste disturbances among patients prescribed glucagon-like peptide-1 receptor agonists.